Ahmed Alanazi/X
May 16, 2025, 08:51
Ahmed Alanazi: Subgroup Insights from EMBER3 Study – Is Combo Better Than SERDs Alone?
Ahmed Alanazi, Department Program Director at King Fahad Medical City, shared a post on X:
“EMBER3 updates subgroups
Co mutation of PIK3CA/ESR1? and prior CDK4/6
Is Combo better than SERDs alone? Subgroups and low number of patients?
Combo showed more benefit! But >60% received palbociclib as prior CDK4/6i”
EMBER-3 Trial Updates from ESMO Breast 2025
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jun 7, 2025, 14:53
Jun 7, 2025, 14:10